13F filer · CIK 873687 ↗

Northwestern University

You are looking at Q3 2022. See the latest, Q3 2026 →

Reported value

$101.6M

+6.5% on the quarter before

Positions

6

2 new · 1 sold out

Top 10

100.0%

of the value

Est. gain

+$1.4M

on stocks held all quarter

Est. return

+1.4%

on those stocks since Q2 2022

Filed

Oct 19, 2022

On SEC EDGAR ↗

Positions as of Sep 30, 2022, from Northwestern University's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

  • New
  • Added
  • Cut
  • Same
  • Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q2 2022. Striped tiles are options.

Berkshire Hathaway Inc Del69%
Agilon Health Inc26%
Ryan Specialty Holdings Inc4.8%

Largest buys

Since Q2 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

  1. Ryan Specialty Holdings Inc~$4.8MNew · 0.0% → 4.8%+119,046 shares
  2. Exicure Inc~$82,000New · 0.0% → 0.1%+52,145 shares

Largest sells

Since Q2 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

  1. Exicure Inc~$113,000Sold out · 0.1% → 0.0%−52,146 shares

Holdings

As of Sep 30, 2022. Changes are in shares against Jun 30, 2022, so a price move alone never reads as a buy or a sale.

Positions, sorted by share of the portfolio
HoldingValue
Berkshire Hathaway Inc DelCL A · shares 0% · price −0.6%69.2%$70.3M−$429,000
Agilon Health IncCOM · shares 0% · price +7.3%25.7%$26.1M+$1.8M
Ryan Specialty Holdings IncCL A · shares New4.8%$4.8M—
Berkshire GreyCOM CL A · shares 0% · price +17.4%0.22%$223,000+$33,000
Exicure IncCOM · shares New0.08%$82,000—
Aptinyx IncCOM · shares 0% · price −34.4%0.04%$40,000−$21,000
Total · 6 positions100%$101.6M+$1.4M

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q2 2022 to Q3 2022: 4 stocks held throughout, up $1.4M (+1.4%).

  1. Agilon Health Inc+$1.8M+7%
  2. Berkshire Grey+$33,000+17%
  3. Aptinyx Inc−$21,000−34%
  4. Berkshire Hathaway Inc Del−$429,000−1%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.

$300.0M$150.0M$0
Q1 2016Q3 2026
Every quarter's filing
Each quarter's 13F filing, newest first
QuarterReported valueFiling
Q3 2026$64.5M+2%SEC ↗
Q2 2026$63.3M+23%SEC ↗
Q1 2026$51.5M−51%SEC ↗
Q4 2025$105.7M+87%SEC ↗
Q3 2025$56.6M+0%SEC ↗
Q2 2025$56.4M−10%SEC ↗
Q1 2025$62.5M+0%SEC ↗
Q4 2024$62.4M−27%SEC ↗
Q3 2024$85.1M−8%SEC ↗
Q2 2024$92.8M−14%SEC ↗
Q1 2024$107.7M−4%SEC ↗
Q4 2023$112.2M−13%SEC ↗
Q3 2023$129.3M+27%SEC ↗
Q2 2023$102.0M−9%SEC ↗
Q1 2023$112.2M+8%SEC ↗
Q4 2022$104.3M+3%SEC ↗
Q3 2022$101.6M+6%SEC ↗
Q2 2022$95.4M−21%SEC ↗
Q1 2022$120.6M+10%SEC ↗
Q4 2021$109.3M+7%SEC ↗
Q3 2021$102.5M−15%SEC ↗
Q2 2021$120.2M+31%SEC ↗
Q1 2021$91.7M−38%SEC ↗
Q4 2020$147.8M−11%SEC ↗
Q3 2020$165.8M+9%SEC ↗
Q2 2020$152.0M+3%SEC ↗
Q1 2020$147.1M−29%SEC ↗
Q4 2019$205.8M+7%SEC ↗
Q3 2019$192.4M−4%SEC ↗
Q2 2019$199.7M+21%SEC ↗
Q1 2019$164.9M+4%SEC ↗
Q4 2018$157.8M−6%SEC ↗
Q3 2018$168.5M+12%SEC ↗
Q2 2018$151.1M−44%SEC ↗
Q1 2018$269.4M+21%SEC ↗
Q4 2017$221.8M+54%SEC ↗
Q3 2017$143.8M+8%SEC ↗
Q2 2017$133.0M+1%SEC ↗
Q1 2017$131.6M+0%SEC ↗
Q4 2016$131.5M−2%SEC ↗
Q3 2016$134.5M+16%SEC ↗
Q2 2016$115.6M+3%SEC ↗
Q1 2016$112.3MSEC ↗

Get the newsletter

The day's AI and market news, in your inbox every weekday.